Today, the FDA approved Rasonque (daraxonrasib), a RAS inhibitor, for treatment of the most common form of pancreatic cancer. Congratulations & thanks to all the scientists, physicians, & patients who dedicated themselves to this moment. This is just the beginning! 💜 www.fda.gov/news-events/...
FDA Approves First in Class Targeted Therapy for Metastatic Pancreatic Cancer
The U.S. Food and Drug Administration today approved Rasonque (daraxonrasib), a RAS inhibitor for the most common form of pancreatic cancer—delivering a new treatment option to patients with advanced ...
fda.gov